- English (USA)
- English (UK)
- English (India)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Janux Therapeutics Inc (JANX)
Janux Therapeutics Inc stock price live, this page displays NASDAQ JANX stock exchange data. View the JANX premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Janux Therapeutics Inc real time stock price chart below.
What Is the Janux Therapeutics Inc Stock Price Today?
The Janux Therapeutics Inc stock price today is 17.47.
What Is the Stock Symbol for Janux Therapeutics Inc?
The stock symbol for Janux Therapeutics Inc is "JANX."
What Stock Exchange Does Janux Therapeutics Inc Trade On?
Janux Therapeutics Inc is listed and trades on the NASDAQ stock exchange.
Is Janux Therapeutics Inc a Good Stock to Buy?
Determining whether Janux Therapeutics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the JANX quote. (ISIN: US47103J1051)
What Is the Janux Therapeutics Inc Stock Price Today?
The Janux Therapeutics Inc stock price today is 17.47.
What Is the Stock Symbol for Janux Therapeutics Inc?
The stock symbol for Janux Therapeutics Inc is "JANX."
What Stock Exchange Does Janux Therapeutics Inc Trade On?
Janux Therapeutics Inc is listed and trades on the NASDAQ stock exchange.
Is Janux Therapeutics Inc a Good Stock to Buy?
Determining whether Janux Therapeutics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the JANX quote. (ISIN: US47103J1051)
17.47
+0.51(+3.03%)
Real-time Data·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
16.96
17.55
52 wk Range
12.12
35.34
JANX is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
16.9617.55
52 wk Range
12.1235.34
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
JANX Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Analysts Sentiment
Strong Buy
Price Target
37.06
Upside
+112.15%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Analysts anticipate sales growth in the current year
Form 8K Janux Therapeutics Inc For: 23 June- Investing.com
Form 4 Janux Therapeutics Inc For: 12 June- Investing.com
- Form 4 Janux Therapeutics Inc For: 31 July
- Investing.com
- Form 4 Janux Therapeutics Inc For: 31 July
- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy
Analyst Ratings
15 Buy
2 Hold
1 Sell
Ratings:
18 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 37.06
(+112.15% Upside)
Earnings
Latest Release
Aug 06, 2026
EPS / Forecast
-0.35 / -0.27
Revenue / Forecast
10.27M / 17.94M
Compare JANX to Peers and Sector
Metrics to compare | JANX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipJANXPeersSector | |
|---|---|---|---|---|
P/E Ratio | −10.4x | −3.7x | −0.3x | |
PEG Ratio | −1.18 | −0.05 | 0.00 | |
Price/Book | 1.1x | 2.6x | 2.6x | |
Price / LTM Sales | 44.4x | 135.7x | 3.1x | |
Upside (Analyst Target) | 88.7% | 133.7% | 50.4% | |
Fair Value Upside | Unlock | 1.5% | 6.4% | Unlock |
Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms technology to treat patients with cancer. The company’s clinical candidates include JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor that is in Phase 1 clinical trial for the treatment of various solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, renal cell carcinoma, small cell lung cancer, pancreatic ductal adenocarcinoma, and triple-negative breast cancer. It also develops JANX011, a CD19-targeted adaptive immune response modulator that is in phase 1 clinical study developed for autoimmune diseases. The company has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates; and Bristol Myers Squibb to develop and commercialize an undisclosed, novel tumor-activated therapeutic targeting a validated solid tumor antigen expressed across several human cancer types. Janux Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the Janux Therapeutics (JANX) Stock Price Today?
The Janux Therapeutics stock price today is 17.47 USD.
What Stock Exchange Does Janux Therapeutics Trade On?
Janux Therapeutics is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Janux Therapeutics?
The stock symbol for Janux Therapeutics is "JANX."
What Is the Janux Therapeutics Market Cap?
As of today, Janux Therapeutics market cap is 1.07B USD.
What Is Janux Therapeutics's Earnings Per Share (TTM)?
The Janux Therapeutics EPS (TTM) is -1.64.
When Is the Next Janux Therapeutics Earnings Date?
Janux Therapeutics will release its next earnings report on Nov 10, 2026.
From a Technical Analysis Perspective, Is JANX a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
How Many Times Has Janux Therapeutics Stock Split?
Janux Therapeutics has split 0 times.
How Many Employees Does Janux Therapeutics Have?
Janux Therapeutics has 113 employees.
What is the current trading status of Janux Therapeutics (JANX)?
As of Aug 19, 2026, Janux Therapeutics (JANX) is trading at a price of 17.47 USD, with a previous close of 16.96 USD. The stock has fluctuated within a day range of 16.96 USD to 17.55 USD, while its 52-week range spans from 12.12 USD to 35.34 USD.
What Is Janux Therapeutics (JANX) Price Target According to Analysts?
The average 12-month price target for Janux Therapeutics is 37.06 USD, with a high estimate of 75 USD and a low estimate of 14 USD. 15 analysts recommend buying the stock, while 1 suggest selling, leading to an overall rating of Strong Buy. The stock has an +112.15% Upside potential.
What Is the JANX Premarket Price?
JANX's last pre-market stock price is 17.13 USD. The pre-market share volume is 784.00, and the stock has decreased by 0.17, or 1.00%.
What Is the JANX After Hours Price?
JANX's last after hours stock price is 16.71 USD, the stock has decreased by -0.25, or -1.47%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.